Search results for "digestive"

showing 10 items of 2631 documents

Anti-tissue transglutaminase antibodies in patients with abnormal liver tests: is it always coeliac disease?

2005

Coeliac disease (CD) is found in 5-10% of patients with chronically abnormal liver tests and no obvious cause of liver disease. In this population the efficacy of screening for CD by anti-tissue transglutaminase (anti-tTG) may be impaired by the high rate of positive anti-tTG found in chronic liver disease.To evaluate the prevalence of coeliac disease and the role of anti-tTG in patients with non-viral, non-autoimmune chronic and no obvious cause of liver damage.Out of 2,512 consecutive patients with abnormal liver tests, 168 (118 men, 50 women; mean age 40.7 +/- 12.6 years) were defined, on the basis of clinical data and liver biopsy, as NAFLD or cryptogenic chronic hepatitis. All were tes…

AdultLiver CirrhosisMalePathologymedicine.medical_specialtyAdolescentTissue transglutaminaseDuodenumBiopsyGastroenterologyCoeliac diseaseGTP-Binding ProteinsInternal medicineBiopsymedicineHumansMass ScreeningIn patientProtein Glutamine gamma Glutamyltransferase 2Aspartate AminotransferasesDuodenoscopyMass screeningAgedAutoantibodiesHepatitis ChronicHepatitisTransglutaminasesHepatologybiologymedicine.diagnostic_testbusiness.industryLiver DiseasesGastroenterologynutritional and metabolic diseasesAlanine TransaminaseMiddle Agedmedicine.diseasedigestive system diseasesImmunoglobulin AFatty LiverCeliac DiseaseLiverImmunoglobulin Gbiology.proteinFemaleAbnormal liverAntibodybusinessThe American journal of gastroenterology
researchProduct

Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis

2019

In patients with nonalcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH) is a risk factor for the development of fibrosis. However, fibrosis has been observed in livers of patients without NASH. We aimed to estimate the prevalence of fibrosis in patients without NASH and risk factors for fibrosis.We analyzed data from 1738 subjects (44.9% with severe obesity) in a cross-sectional liver biopsy cohort enrolled at referral centers in Italy and Finland. Biopsy specimens were analyzed histologically by a blinded pathologist at each center, and a diagnosis of NASH was made based on steatosis (≥5% of hepatocytes), hepatocellular ballooning, and lobular inflammation. We also c…

AdultLiver CirrhosisMalemedicine.medical_specialtyBiopsydigestive systemGastroenterologyRisk Assessment03 medical and health sciences0302 clinical medicineFibrosisNon-alcoholic Fatty Liver DiseaseInternal medicineNonalcoholic fatty liver diseaseBiopsymedicinePrevalenceHumansrisk factorsRisk factorhistory; inflammatory response; progression; risk factorsHepatologymedicine.diagnostic_testbusiness.industryFatty liverGastroenterologynutritional and metabolic diseasesinflammatory responsemedicine.diseasedigestive system diseasesFatty LiverCross-Sectional StudiesItalyLiver030220 oncology & carcinogenesisLiver biopsyCohort030211 gastroenterology & hepatologyFemalehistoryprogressionSteatohepatitisbusiness
researchProduct

Hepatocellular carcinoma in cirrhotic patients at multidetector CT: hepatic venous phase versus delayed phase for the detection of tumour washout.

2011

OBJECTIVES: Our aim was to compare retrospectively hepatic venous and delayed phase images for the detection of tumour washout during multiphasic multidetector row CT (MDCT) of the liver in patients with hepatocellular carcinoma (HCC). METHODS: 30 cirrhotic patients underwent multiphasic MDCT in the 90 days before liver transplantation. MDCT was performed before contrast medium administration and during hepatic arterial hepatic venous and delayed phases, images were obtained at 12, 55 and 120 s after trigger threshold. Two radiologists qualitatively evaluated images for lesion attenuation. Tumour washout was evaluated subjectively and objectively. Tumour-to-liver contrast (TLC) was measured…

AdultLiver CirrhosisMalemedicine.medical_specialtyCarcinoma Hepatocellularmedicine.medical_treatmentLiver transplantationLesionmedicineHumansRadiology Nuclear Medicine and imagingAgedRetrospective StudiesFull Paperbusiness.industryLiver NeoplasmsLiver CT HCCWashoutVenous phaseGeneral MedicineDelayed phaseMiddle AgedHCCSmedicine.diseasedigestive system diseasesLiver TransplantationContrast mediumHepatocellular carcinomaFemaleRadiologymedicine.symptomSettore MED/36 - Diagnostica Per Immagini E RadioterapiaTomography X-Ray Computedbusiness
researchProduct

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication

2017

Background & Aims: The risk of hepatocellular carcinoma (HCC) is reduced but not eradicated among patients with hepatitis C virus (HCV)-induced advanced hepatic fibrosis who attained sustained viral response (SVR). We aimed to assess the risk of cirrhosis-related complications in this specific group of patients. Methods: Data from previously reported Western cohort studies including patients with chronic HCV infection and bridging fibrosis or cirrhosis who attained SVR were pooled for survival analyses on the individual patient level. The primary endpoint was HCC and the secondary endpoint was clinical disease progression, defined as liver failure, HCC or death. Results: Included were 1…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisCarcinoma HepatocellularSustained Virologic ResponseHepatitis C virusmedicine.disease_causeGastroenterologyCohort Studies03 medical and health sciencesLiver disease0302 clinical medicineSDG 3 - Good Health and Well-beingRisk FactorsDiabetes mellitusInternal medicinemedicineClinical endpointHumansAgedProportional Hazards ModelsRetrospective StudiesHepatologybusiness.industryIncidenceLiver NeoplasmsRetrospective cohort studyHepatitis C ChronicMiddle Agedmedicine.diseasedigestive system diseases030220 oncology & carcinogenesisHepatocellular carcinomaHCVDisease Progression030211 gastroenterology & hepatologyFemalebusinessLiver cancer
researchProduct

Evaluation of 24-hour gastric acidity in patients with hepatic cirrhosis.

1996

Data from previous studies on gastric acid secretion in patients with hepatic cirrhosis are controversial, due, at least in part, to the possible interference of liver failure and altered gastric mucosal microcirculation on the pharmacological action of the substances used to stimulate the parietal cell. For this reason, we wished to investigate the circadian pattern of gastric acidity by means of continuous 24-hour pH monitoring, which permits measurement of pH fluctuations in a nearly physiological manner and does not require any pharmacological stimulus.Forty-nine patients with liver cirrhosis of different aetiology were recruited for this study. They underwent 24-hour gastric pH-metry w…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisGastroenterologyGastric AcidReference ValuesInternal medicinemedicineHumansCircadian rhythmProspective StudiesProspective cohort studyAntrumParietal cellAgedHepatologybiologybusiness.industryStomachdigestive oral and skin physiologyHelicobacter pyloriHydrogen-Ion ConcentrationMiddle Agedmedicine.diseasebiology.organism_classificationCircadian Rhythmmedicine.anatomical_structureGastric MucosaGastric acidFemalebusiness
researchProduct

Cirrhosis of mixed etiology (hepatitis C virus and alcohol): Posttransplantation outcome-Comparison with hepatitis C virus-related cirrhosis and alco…

2008

Hepatitis C virus (HCV)-related liver disease is enhanced by alcohol consumption. Of HCV-related liver transplantation (LT) recipients, 25% have a history of alcohol intake. The purpose of this research was to determine whether LT outcome differs between patients with cirrhosis of mixed etiology compared to HCV or alcohol alone. Of 494 LT (1997-2001), recipient/donor features, post-LT histological, metabolic complications [hypertension, diabetes-diabetes mellitus (DM)], and de novo tumors were compared in 3 groups [HCV-related cirrhosis = 170 (HCV group), alcohol-related cirrhosis (alcohol group) = 107, and cirrhosis of mixed etiology (mixed group) = 60]. Protocol biopsies were done in HCV …

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis C virusmedicine.medical_treatmentHepacivirusLiver transplantationmedicine.disease_causeGastroenterologyBody Mass IndexLiver diseasePostoperative ComplicationsLiver Cirrhosis AlcoholicInternal medicineHumansMedicineAgedTransplantationHepatologybusiness.industryIncidence (epidemiology)Graft Survivalvirus diseasesMiddle Agedmedicine.diseaseHepatitis Cdigestive system diseasesLiver TransplantationTreatment OutcomeHepatocellular carcinomaEtiologyFemaleSurgerybusinessBody mass indexImmunosuppressive AgentsLiver Transplantation
researchProduct

Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection

1999

Non-insulin-dependent diabetes mellitus (NIDDM) may be associated with chronic hepatitis C virus (HCV) infection. This was studied further in two parts. First, 1,151 patients with HCV-related cirrhosis and 181 patients with hepatitis B virus (HBV)-related cirrhosis, well matched for age, sex, and severity of cirrhosis, were reviewed retrospectively. The prevalence of diabetes mellitus was higher in HCV-related cirrhosis (23.6%) than in HBV-related cirrhosis (9.4%; odds ratio [OR], 2.78; 95% confidence interval [CI], 1.6-4.79; P =.0002). The prevalence of diabetes mellitus was associated closely with the Child-Pugh score (OR, 3.83; 95% CI, 2. 38-6.17; P.0001) and increasing age (OR, 1.02; 95…

AdultLiver CirrhosisMalemedicine.medical_specialtyCirrhosisHepatitis Viral Humanmedicine.medical_treatmentmedicine.disease_causeGastroenterologyInsulin resistanceInternal medicineDiabetes mellitusmedicineHumansInsulinProspective StudiesAgedRetrospective StudiesHepatitis B virusGlucose tolerance testHepatologymedicine.diagnostic_testbusiness.industryInsulinFlaviviridaeOdds ratioHepatitis C ChronicMiddle AgedHepatitis Bmedicine.diseasedigestive system diseasesEndocrinologyDiabetes Mellitus Type 2FemalebusinessViral hepatitisHepatology
researchProduct

Focal lesions in cirrhosis: Not always HCC.

2017

Even though most hepatocellular carcinomas (HCC) develop in the setting of cirrhosis, numerous other focal liver lesions and pseudolesions may be encountered. The role of the radiologist is therefore to differentiate these lesions from HCC to avoid under- and overdiagnosis. There are several ways of classifying these lesions: those which predate the development of fibrosis and cirrhosis (cystic lesions, hemangioma), those related to or a consequence of cirrhosis (regenerative nodules, dysplastic nodules, focal fibrosis, peribiliary cysts, shunts, or even cholangiocarcinoma), and those related to the underlying cause of chronic liver disease (lymphoma). Finally, some may develop independentl…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisCarcinoma HepatocellularBile Duct NeoplasmChronic liver disease030218 nuclear medicine & medical imagingHemangiomaCholangiocarcinomaDiagnosis Differential03 medical and health sciences0302 clinical medicineFibrosismedicineHumansRadiology Nuclear Medicine and imagingOverdiagnosisAgedAged 80 and overmedicine.diagnostic_testbusiness.industryCystsLiver NeoplasmsMagnetic resonance imagingGeneral MedicineMiddle Agedmedicine.diseaseMagnetic Resonance Imagingdigestive system diseasesBile Ducts IntrahepaticBile Duct Neoplasms030211 gastroenterology & hepatologyFemaleRadiologyDifferential diagnosisbusinessHemangiomaTomography X-Ray ComputedEuropean journal of radiology
researchProduct

Interleukin-6 and its soluble receptor in patients with liver cirrhosis and hepatocellular carcinoma.

2006

AIM: To evaluate the immunohistochemical localization of interleukin-6 (IL-6) and IL-6 receptor (IL-6R) on tumor tissue specimens from patients with hepatocellular carcinoma (HCC) and the serum levels of IL-6 and sIL-6R in a group of patients with HCC as well as liver cirrhosis (LC) in a group of patients with LC alone and in a control group. METHODS: Three groups of subjects were studied: group I (n = 83) suffering from HCC and LC, group II (n = 72) suffering from LC alone and group III (n = 42) as healthy controls. All patients had hepatitis C virus infection. Serum IL-6 and IL-6R levels were determined using a commercially available ELISA kit. Immunohistochemistry was performed using the…

AdultLiver CirrhosisMalemedicine.medical_specialtyPathologyCirrhosisCarcinoma Hepatocellularmedicine.medical_treatmentChronic liver diseaseGastroenterologyInternal medicineCarcinomaMedicineHumansInterleukin 6ReceptorCytokineAgedNeoplasm Stagingbiologybusiness.industryInterleukin-6Chronic liver diseaseLiver NeoplasmsGastroenterologyGeneral MedicineMiddle Agedmedicine.diseaseImmunohistochemistryReceptors Interleukin-6digestive system diseasesCytokineHepatocellular carcinomabiology.proteinImmunohistochemistryFemalebusinessRapid CommunicationWorld journal of gastroenterology
researchProduct

Predictors of mortality in patients under treatment for chronic hepatitis B in Ethiopia: a prospective cohort study

2019

Abstract Background Antiviral treatment for chronic hepatitis B (CHB) is largely unavailable in sub-Saharan Africa; hence, little is known about the prognosis after initiating treatment in African CHB patients. In this study we aimed to assess predictors of mortality in one of the largest CHB cohorts in sub-Saharan Africa. Methods Two-hundred-and-seventy-six CHB patients who started treatment with tenofovir disoproxil fumarate at a public hospital in Ethiopia between March 18, 2015, and August 1, 2017, were included in this analysis. Patients were followed up until October 1, 2017, and deaths were ascertained through hospital records and telephone interview with relatives. Decompensated cir…

AdultLiver CirrhosisMalemedicine.medical_specialtyTime FactorsSurvivalAdolescentEpidemiologyPhysical examinationAntiviral therapyAntiviral AgentsBody Mass Index03 medical and health sciencesYoung Adult0302 clinical medicineHepatitis B ChronicInterquartile rangeRisk FactorsInternal medicineEpidemiologyMedicineHumansProspective Studieslcsh:RC799-869Prospective cohort studyTenofovirProportional Hazards Modelsmedicine.diagnostic_testbusiness.industryHazard ratioGastroenterologyAge FactorsGeneral MedicineHepatitis BHepatologyMiddle Agedmedicine.diseaseHepatitis BResource-limited settingsSurvival RateVDP::Medisinske Fag: 700::Helsefag: 800030220 oncology & carcinogenesislcsh:Diseases of the digestive system. Gastroenterology030211 gastroenterology & hepatologyFemaleEthiopiabusinessBody mass indexResearch Article
researchProduct